Download presentation
Presentation is loading. Please wait.
Published byChristian Armstrong Modified over 9 years ago
1
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard Medical School
2
Patient Selection PSA DT is significantly associated with time to cancer-specific death following PSA failure –Multi-institutional RTOG 9202 (RT + short vs. long-term H) CaPSURE/CPDR (RP or RT) –Single Institution Johns Hopkins (H Rx delayed until BS +) Barnes Jewish (Prospective Screening Study)
3
Arm 1: goserelin and flutamide 2 mos before and during standard RT (STAD) Arm 2: goserelin and flutamide 2 mos before and during standard RT, followed by goserelin alone for 24 mos (LTAD) T2c-T4 Pre Rx PSA < 150 ng/ml N = 1513 RANDOMIZERANDOMIZE RTOG 92-02
4
RTOG <0.0001 [4.3, 8.9]6.2 P-Value[95% C.I.]Hazard Ratio Interpretation Men whose PSA is doubling less than every 12 months are ~ 6 times at greater risk of prostate cancer death than those with a slower doubling time.
5
RTOG 9202 Prostate Cancer Survival by PSA-DT Years since randomization Prostate Cancer Survival Rate PSA DT < 12 months PSA DT 12 months
6
N = 1451
7
CaPSURE/CPDR <0.0001 [12.5, 30.9]19.6 P-Value[95% C.I.]Hazard Ratio Interpretation Men whose PSA is doubling less than every 3 months are ~ 20 times at greater risk of prostate cancer death than those with a slower doubling time.
8
N = 341
9
051015 0.0 0.25 0.50 0.75 1.0 Years after Biochemical Recurrence Prostate Cancer Specific Survival Number at risk <3.0: 23 10 2 0 3.0-8.9: 119 85 19 0 9.0-14.9: 79 51 19 3 >15 158 113 52 9 PSADT < 3.0 months PSADT 9.0 - 14.9 months PSADT 3.0 - 8.9 months PSADT > 15.0 months p<0.001, log-rank PSA DT (continuous)AHR: 0.86 [0.8, 0.9] p < 0.001
10
SUMMARY Patient Selection PSA DT is significantly associated with PCM –RP –RT –RT + short term H –RT + long term H PSA DT < 3 months –Poor Prognostic Group 15-20% of PSA failure in general population 6-7% of PSA failure in a screened population
11
Clinical Practice In the US, for patients with a rising PSA, the rate of rise of PSA influences use of hormonal therapy –CaPSURE Median time to metastases following PSA failure in patients with a PSA DT < 3 months –18 months Johns Hopkins Patients with a PSA DT < 3 months are offered hormonal therapy
12
Treatment Arms Hormonal Therapy Systemic Therapy –Taxotere Survival benefit in men with HRMPC –Other Agents
13
End Points Primary –Time to Bone Metastases Secondary –Time to Cancer-Specific Death –Time to all cause Death PSA –What is the evidence to suggest an association between a PSA nadir > 0.2 ng/ml and cancer-specific death in men treated with hormonal therapy for a rising PSA?
14
PSA Nadir > 0.2 Following Hormonal Therapy for a Rising PSA Multi-institutional –CaPSURE/CPDR Single Institutions –MSKCC –Harvard and Barnes Jewish
15
METHODOLOGY MSKCC –346 RP (81% BS negative) Cox Regression –End point Time to PCSM following 8 months of hormonal therapy –Covariates PSA level at initiation of hormonal therapy Pre-hormonal therapy PSA DT PSA nadir within 8 months of Hormonal therapy Prostatectomy T-category Gleason score Bone scan status
16
RESULTS –PSA nadir < 0.2 ng/ml< 0.0001 –PSA level (continuous)< 0.0001 –PSA DT > 3 months0.03 –Gleason score0.40 –pT20.40 –Bone scan status0.60 –63 prostate cancer deaths Median cancer specific survival for patients with PSA nadir > 0.2 –4.8 [2.6, 7.1] years
19
METHODOLOGY 44 Institutions – CPDR and CaPSURE –486 RP; 261 RT –Bone scan (-) Cox Regression –End point Time to PCSM following 8 months of hormonal therapy –Covariates PSA level at initiation of hormonal therapy Pre-hormonal therapy PSA DT PSA nadir within 8 months of Hormonal therapy Interval to PSA failure following RP or RT Gleason score Initial Local Therapy Age at time of PSA nadir
20
RESULTS –PSA nadir (continuous)< 0.0001 –PSA DT (continuous)0.002 –PSA level (continuous)< 0.0001 –Gleason 8 to 100.01 –Gleason 70.17 –Interval to PSA failure (cont)0.20 –Initial Local rx0.19 –Age at PSA nadir0.96 53 deaths –28 Prostate Cancer Specific Adjusted HR for PCSM when PSA nadir > 0.2 20 [7, 61; p < 0.0001]
21
7-yr cumulative incidence estimates of PCSM with 95% CI PSA nadir PSA DT < 3 mos PSA DT < 6 mos PSA DT < 9 mos N pts N PC deaths 7 yr PCSM [95%CI] N pts N PC deaths 7 yr PCSM [95%CI] N pts N PC deaths 7 yr PCSM [95%CI] > 0.2 6821 72 [45, 99] 10323 55 [30, 80] 126 24 54 [28, 80] 0.2 1563 4 [0.1, 9] 3134 3 [0.1, 6] 431 4 2 [0.1, 5]
22
68/224 ~ 30%
23
103/416 ~25%
24
126/557~ 22%
25
SUMMARY PSA DT < 3 months –30% did not nadir PSA on AST Hormone resistant –Accounted for nearly all PC death »Single institution data base »Multi-institutional data base –AST + Docetaxel If PSA nadir > 0.2 –Hormone and Docetaxel resistant --- cancer death If PSA nadir > 0.2 decreased from 30% on AST to 10% on AST + Docetaxel, would this be likely to produce clinical benefit?
26
DISCUSSION Is PSA nadir > 0.2 following 8 months of AST (assuming castrate T) a clinically significant end point? In a phase III RCT if the proportion of men with a PSA nadir > 0.2 declined from 30% on AST to 10% on AST + Taxotere, would this be likely to provide clinical benefit? –Prolonged time to bone metastases –Prolonged time to cancer death
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.